Who
Katina Dorton
Director
Company insider
Files Form 4 as: Director, Keenova Therapeutics; Director, Fulcrum Therapeutics; Director, Prelude Therapeutics; Director, TScan Therapeutics; Director, US Ecology; Director, Pandion Therapeutics; Director, US Ecology Holdings; Chief Financial Officer, Tectonic Therapeutic.
In numbers
- Trades disclosed
- 67
- Buys
- 4
- Sells
- 4
- Bought
- $157K
- Sold
- $231K
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 19 Aug 2014
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code A | —4,406 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code A | —4,406 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | Keenova Therapeutics | SEC FORM 4 Code M | —4,882 | filing |
| 2 Jun 2026filed 4 Jun 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code M | —4,882 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code M | —4,882 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | Keenova Therapeutics | SEC FORM 4 Code M | —4,882 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,984 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,984 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Keenova Therapeutics | SEC FORM 4 Code M | —1,808 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Keenova Therapeutics | SEC FORM 4 Code F | —513 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,480 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,480 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code M | —1,808 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | Keenova Therapeuticsoption or derivative | SEC FORM 4 Code M | —1,808 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.